This HTML5 document contains 52 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n21http://localhost/temp/predkladatel/
n20http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14740%2F11%3A00055489%21RIV12-MSM-14740___/
n15http://linked.opendata.cz/resource/domain/vavai/projekt/
n11http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n17http://linked.opendata.cz/resource/domain/vavai/subjekt/
n16http://linked.opendata.cz/ontology/domain/vavai/
n12http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n14http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14740%2F11%3A00055489%21RIV12-MSM-14740___
rdf:type
skos:Concept n16:Vysledek
rdfs:seeAlso
http://www.ncbi.nlm.nih.gov/pubmed/22167136
dcterms:description
The drug-drug interactions can result in alterations of the therapeutical responses. The present study was designed to investigate possible pharmacokinetic interactions between the cognitive agent memantine and the antidepressant fluoxetine combined often in treatments of cognitive disorders including Alzheimer disease. The attention was focused on changes of the cytochrome P450 2D2 isoenzyme activity in two animal models. METHODS AND DESIGN: The tested drugs were administered alone or in a combination to rat males and their effects on the 2D2 isoenzyme activity was determined after in vivo administration. The levels of marker dextromethorphan, its 2D2 specific metabolite dextrorphan were analyzed in plasma of rats and using the model of isolated perfused rat liver in the perfusion medium. The dextromethorphan/ dextrorphan (DEM/DEX) metabolic ratios were determined as a sign of inhibitory influences on CYP2D2. The drug-drug interactions can result in alterations of the therapeutical responses. The present study was designed to investigate possible pharmacokinetic interactions between the cognitive agent memantine and the antidepressant fluoxetine combined often in treatments of cognitive disorders including Alzheimer disease. The attention was focused on changes of the cytochrome P450 2D2 isoenzyme activity in two animal models. METHODS AND DESIGN: The tested drugs were administered alone or in a combination to rat males and their effects on the 2D2 isoenzyme activity was determined after in vivo administration. The levels of marker dextromethorphan, its 2D2 specific metabolite dextrorphan were analyzed in plasma of rats and using the model of isolated perfused rat liver in the perfusion medium. The dextromethorphan/ dextrorphan (DEM/DEX) metabolic ratios were determined as a sign of inhibitory influences on CYP2D2.
dcterms:title
Effects of combined treatment with cognitive enhancer memantine and antidepressant fluoxetine on CYP2D2 metabolic activity in rats Effects of combined treatment with cognitive enhancer memantine and antidepressant fluoxetine on CYP2D2 metabolic activity in rats
skos:prefLabel
Effects of combined treatment with cognitive enhancer memantine and antidepressant fluoxetine on CYP2D2 metabolic activity in rats Effects of combined treatment with cognitive enhancer memantine and antidepressant fluoxetine on CYP2D2 metabolic activity in rats
skos:notation
RIV/00216224:14740/11:00055489!RIV12-MSM-14740___
n16:predkladatel
n17:orjk%3A14740
n3:aktivita
n13:P n13:Z
n3:aktivity
P(ED1.1.00/02.0068), Z(MSM0021622404)
n3:cisloPeriodika
5
n3:dodaniDat
n14:2012
n3:domaciTvurceVysledku
n11:3007251 n11:5581966 n11:1309137 n11:2095971 n11:2150573
n3:druhVysledku
n9:J
n3:duvernostUdaju
n19:S
n3:entitaPredkladatele
n20:predkladatel
n3:idSjednocenehoVysledku
196615
n3:idVysledku
RIV/00216224:14740/11:00055489
n3:jazykVysledku
n10:eng
n3:klicovaSlova
cytochrome P450; memantine; fluoxetine; rat; inhibition
n3:klicoveSlovo
n8:inhibition n8:rat n8:memantine n8:fluoxetine n8:cytochrome%20P450
n3:kodStatuVydavatele
SE - Švédské království
n3:kontrolniKodProRIV
[D674B8877633]
n3:nazevZdroje
Neuroendocrinology Letters
n3:obor
n18:FR
n3:pocetDomacichTvurcuVysledku
5
n3:pocetTvurcuVysledku
5
n3:projekt
n15:ED1.1.00%2F02.0068
n3:rokUplatneniVysledku
n14:2011
n3:svazekPeriodika
32
n3:tvurceVysledku
Zendulka, Ondřej Šulcová, Alexandra Juřica, Jan Zahradníková, Lucia Sabová, Michaela
n3:wos
000300543900026
n3:zamer
n12:MSM0021622404
s:issn
0172-780X
s:numberOfPages
6
n21:organizacniJednotka
14740